Dr Reddys Laboratories
Dr. Reddy's Laboratories, a prominent player in the global pharmaceutical industry, is headquartered in Hyderabad, India. Founded in 1984, the company has established itself as a leader in the development and manufacturing of a wide range of generic medications, active pharmaceutical ingredients (APIs), and proprietary products. With a strong presence in markets across North America, Europe, and Asia, Dr. Reddy's is committed to providing affordable healthcare solutions. The company’s core offerings include generic formulations, biosimilars, and over-the-counter products, distinguished by their quality and innovation. Dr. Reddy's has achieved significant milestones, including numerous product launches and strategic partnerships, solidifying its market position. Recognised for its commitment to sustainability and patient-centric approach, Dr. Reddy's Laboratories continues to make strides in enhancing global health outcomes.
DitchCarbon Score
How does Dr Reddys Laboratories's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Dr Reddys Laboratories's score of 89 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Dr Reddys Laboratories's reported carbon emissions
In 2024, Dr. Reddy's Laboratories reported total carbon emissions of approximately 1,171,177,000 kg CO2e, comprising 189,530,000 kg CO2e from Scope 1, 114,655,000 kg CO2e from Scope 2, and 866,992,000 kg CO2e from Scope 3 emissions. This reflects a significant commitment to reducing their carbon footprint, with a target of achieving a 55% reduction in absolute emissions by 2030, based on 2018 levels. The company has set ambitious goals to reach carbon neutrality by 2030, focusing on both Scope 1 and Scope 2 emissions. They aim to source 50% of their energy from renewable sources by FY 2025 and 100% by FY 2030. Additionally, Dr. Reddy's Laboratories has committed to reducing Scope 1 and 2 greenhouse gas emissions by 50.2% per million USD revenue by FY 2031, which translates to a 25% absolute reduction from a FY 2021 baseline. For Scope 3 emissions, they target a 12.3% reduction within the same timeframe. Dr. Reddy's Laboratories is actively engaging in global climate action, aligning their strategies with industry standards to mitigate their environmental impact. Their comprehensive approach underscores a commitment to sustainability and responsible corporate practices in the pharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 349,108,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 195,287,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | 345,407,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Dr Reddys Laboratories is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
